Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Urothelial Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Baptist Alliance MCI, Miami, Florida, United States

  • Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States

    Contact: Study coordinator (David Aggen, MD, PhD) · 646-422-4679
  • Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

    Contact: Study coordinator (David Aggen, MD, PhD) · 646-422-4679
  • Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

    Contact: Study coordinator (David Aggen, MD, PhD) · 646-422-4679
  • Memorial Sloan Kettering -Nassau, Commack, New York, United States

    Contact: Study coordinator (David Aggen, MD, PhD) · 646-422-4679
  • Memorial Sloan Kettering Westchester, Harrison, New York, United States

    Contact: Study coordinator (David Aggen, MD, PhD) · 646-422-4679
  • Memorial Sloan Kettering Cancer Center, New York, New York, United States

    Contact: Study coordinator (David Aggen, MD, PhD) · 646-422-4679
    Contact: Study coordinator (Jonathan Rosenberg, MD) · 646-422-4461
  • Memorial Sloan Kettering Nassau, Rockville Centre, New York, United States

    Contact: Study coordinator (David Aggen, MD, PhD) · 646-422-4679
  • Lehigh Valley Health Network (Data Collection Only), Allentown, Pennsylvania, United States

  • University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States

Study leads
  • David Aggen, MD, PhD

    Principal Investigator

    Memorial Sloan Kettering Cancer Center